公开(公告)号：US20200172532A1

公开(公告)日：2020-06-04

申请号：US16624140

申请日：2018-06-26

Applicant: Janssen Pharmaceutica NV

Inventor： Zhao-Kui WAN ,  Yimin JIANG ,  Xuedong DAI ,  Qian LIU ,  Wing Shun CHEUNG ,  Gang DENG ,  Liqiang FU

IPC: C07D417/14 ,  C07D401/04 ,  C07D417/04 ,  A61P31/20

Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

公开(公告)号：US20230142285A1

公开(公告)日：2023-05-11

申请号：US17604818

申请日：2020-12-17

Applicant: Janssen Pharmaceutica NV

Inventor： Wei CAI ,  Xuedong DAI ,  Oliver Alexis Georges QUEROLLE ,  Johannes Wilhelmus John F. THURING ,  Yingtao LIU ,  Lianzhu LIU ,  Yanping XU ,  Liqiang FU ,  Ming LI ,  Lichao FANG ,  Xianguin DENG ,  Qiwu ZHAO ,  Kangying LI ,  Alicia Tee Fuay NG ,  Nicolas Freddy J. DARVILLE ,  Edward CLEATOR ,  Gregor Thomas URBANIETZ ,  William Marc MATON ,  Vineet PANDA

IPC: C07D487/10 ,  C07D207/08 ,  A61P35/00

CPC classification number: C07D487/10 ,  C07D207/08 ,  A61P35/00

Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN); and diabetes.

公开(公告)号：US20230039917A1

公开(公告)日：2023-02-09

申请号：US17734413

申请日：2022-05-02

Applicant: Janssen Pharmaceutica NV

Inventor： Xuedong DAI ,  Olivier Alexis Georges QUEROLLE ,  Daniel Jason KROSKY ,  Wei CAI ,  Liqiang FU ,  Linglong KONG ,  Yingtao LIU ,  Zhao-Kui WAN ,  Barbara MORSCHHÄUSER GEB. HERKERT ,  Vineet PANDE ,  James Patrick EDWARDS ,  Aaron Nathaniel PATRICK ,  Patrick René ANGIBAUD ,  Virginie Sophie PONCELET

IPC: C07D495/04 ,  A61P35/00 ,  C07D519/00

Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.